29 jun: Mærsk: Clarkson udforderer bankerne med analysedækning
29 jun: Danske/Berenberg: Den mindst foretrukne blandt nordiske banker
29-06-2012 07:30:51

Regulated information - Ageas communicates on revised total number of issued shares

Relateret indhold
31 jan - 
Tirsdagens aktier: Chr H i top, mens Novo og Genmab ble..
31 jan - 
Tirsdagens aktier: Chr H i top, mens Novo og Genmab for..
31 jan - 
Aktier/middag: Med Chr. Hansen, Mærsk og Europa i plus
Relateret debat
22 mar - 
Jeg løste det ved at gå på forsiden og derpå tilbage ti..
22 mar - 
Det samme her,det har nu varet et par dage,har været så..
22 mar - 
De sidste par dage har den været tilbage til normalen i..

Following the cancellation of the shares bought back during the buy-back programme launched in August 2011, the total number of issued shares (the 'denominator') has fallen to 2,431,212,726.

At the end of January Ageas completed its share buy-back programme for a total amount of EUR 250 million, representing 192,168,091 shares. The General Meetings of Shareholders already approved at the end of April 2012 the cancellation of these shares but the Dutch law allows for a 2 month period of objection. As this period is now at an end, the shares have been cancelled, and as a result, the total amount of issued shares is reduced to 2,431,212,726. As from today, this number will be used to calculate percentage shareholdings.

As a further consequence, and in accordance with the rules on financial transparency, Ageas confirms that its interest fell below the threshold of 3% on 29 June 2012.

The transparency information is available on the Ageas website under "Investor relations - The share - Transparency requirements" (http://www.ageas.com/en/Pages/transparency_requirements.aspx). 

Ageas is an international insurance company with a heritage spanning more than 180 years. Ranked among the top 20 insurance companies in Europe, Ageas has chosen to concentrate its business activities in Europe and Asia, which together make up the largest share of the global insurance market. These are grouped around four segments: Belgium, United Kingdom, Continental Europe and Asia and served through a combination of wholly owned subsidiaries and partnerships with strong financial institutions and key distributors around the world. Ageas operates successful partnerships in Belgium, UK, Luxembourg, Italy, Portugal, Turkey, China, Malaysia, India and Thailand and has subsidiaries in France, Hong Kong and UK. It is the market leader in Belgium for individual life and employee benefits, as well as a leading non-life player, through AG Insurance, and in the UK, it has a strong presence as the third largest player in private car insurance and the over 50's market. It employs more than 13,000 people and has annual inflows of more than EUR 17 billion.

MEDIA CONTACT

+32 (0)2 557 57 37 / +32 (0) 479 79 50 02

INVESTOR RELATIONS

Brussels

+32 (0)2 557 57 33

Utrecht

+31 (0)30 252 53 05

Ageas

Rue du Marquis 1 - 1000 Brussels - Belgium

Archimedeslaan 6 - 3584 BA Utrecht - The Netherlands

www.ageas.com

Notification

Pdf version press release


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Ageas via Thomson Reuters ONE

HUG#1622732

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 mar
EI
Til EI: Jeg kan på min PC ikke få vist de 2 knapper "Nyt emne" og "Næste side". Hvordan løses det pr..
1
22 mar
EI
Det er vel fordi EI af erfaring ved at folk ikke gider læse mere end 4 maks 5 linjer ;-)!
1

Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY

24-03-2017 13:31:36
Udvalget for humanmedicinske lægemidler (CHMP) ved Det Europæiske Lægemiddelsagentur (EMA) har tildelt Novo Nordisks Refixia en positiv udtalelse og anbefaler en markedsføringstilladelse.Det skriver Novo Nordisk i en fondsbørsmeddelelse.CHMP anbefaler en markedsføringstilladelse til Refixia til unge og voksne med hæmofili B. Til grund for anbefalingen ligger resultater fra udviklingsprogrammet par..

Novo/Exane: Kursmålet skæres til 270 kr.

24-03-2017 10:17:22
Den franske storbank Exane BNP Paribas skærer kursmålet for aktien i Novo Nordisk til 270 kr. fra 295 kr. Anbefalingen er uændret "outperform", viser data fra Bloomberg.Novo-aktien falder fredag 0,4 pct., eller 1 kr., til 233,20 kr. Det dækker dog over en stigning, da aktien ikke længere handles inklusive retten til et udbytte på 4,60 kr./ritzau/FINANSJakob Dalskov +45 33 30 03 35 Ritzau Finans, E..

Aktier/tendens: Mulighed for mere gas til Mærsk i ventet rødt C20

24-03-2017 08:31:54
Det danske aktiemarked kan fredag blive præget af små udsving med en lille overvægt af negative fortegn.A.P. Møller-Mærsks B-aktie var uændret efter torsdagens handel og blev handlet til 11.500 kr. Aktien kan dog gå fra grå til grøn fredag, da der er potentielt gode nyheder til det danske konglomerat.Efter en Nordsø-aftale, der kan redde det ellers lukningstruede Tyra-felt, skriver Jyllands-Posten..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Euroinvestor.com A/S 11,90 0,9% Stigning i aktiekurs
Ageas 36,09 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. marts 2017 02:43:20
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB5 - 2017-03-27 02:43:20 - 2017-03-27 02:43:20 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x